Eddie Reed
National Institutes of Health · 199 works · 8,596 citations · h-index 49
Top works
- Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group
- Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panel
- The impact of disease severity on the informed consent process in clinical research
- Lack of Correlation Between Prostate-Specific Antigen and the Presence of Measurable Soft Tissue Metastases in Hormone-Refractory Prostate Cancer
- When chronic conditions become acute: prevention and control of chronic diseases and adverse health outcomes during natural disasters.
- Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer
- Apigenin inhibits VEGF and HIF‐1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways
- Steady-state plasma concentrations and effects of taxol for a 250 mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer
- Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells.
- Allopurinol kinetics
- Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3
- Excision repair cross complementing-group 1: Gene expression and platinum resistance (Review) parameters in human breast cancer
- A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues
- Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer.
- A Phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis
- Phase I Clinical Trial of Oral COL-3, a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer
- Pharmacokinetics of thalidomide in an elderly prostate cancer population
- Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review)
- The measurement of cisplatin-DNA adduct levels in testicular cancer patients
- The Pharmacokinetics of TNP‐470, a New Angiogenesis Inhibitor